Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (211-220 of 502) with videos related to

Pageof 51
Sort By:
Oncogene|July 19, 2019
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradationLiang Deng, Guoqing Qian, Shuo Zhang, et al.
JTO Clinical and Research Reports|June 3, 2024
Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having <i>EGFR</i> Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ StudyMadhusmita Behera, Renjian Jiang, Zhonglu Huang, et al.
JCO Oncology Practice|July 8, 2026
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine NeoplasmsJennifer W Carlisle, Katherine O'Reilly, Xiyuan Angel Ji, et al.
Cancer Chemotherapy and Pharmacology|May 27, 2014
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)Rathi N Pillai, Joseph Aisner, Suzanne E Dahlberg, et al.
World Journal of Oncology|October 7, 2017
Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United StatesOlatunji B Alese, Sungjin Kim, Zhengjia Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)Suresh S Ramalingam, Ju-Whei Lee, Chandra P Belani, et al.
Cancer|February 1, 2017
Discussing molecular testing in oncology care: Comparing patient and physician information preferencesAna P M Pinheiro, Rachel H Pocock, Jeffrey M Switchenko, et al.
Molecular Cancer|April 12, 2019
Small Molecule KRAS Agonist for Mutant KRAS Cancer TherapyKe Xu, Dongkyoo Park, Andrew T Magis, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
Innovative Clinical Trials: The LUNG-MAP StudyC E Steuer, V Papadimitrakopoulou, R S Herbst, et al.
American Journal of Clinical Oncology|January 29, 2015
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak TrialsCorey J Langer, Mark A Socinski, Jyoti D Patel, et al.
Pageof 51

Showing results (211-220 of 502) with videos related to

Sort By:
Pageof 51
Oncogene|July 19, 2019
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradationLiang Deng, Guoqing Qian, Shuo Zhang, et al.
JTO Clinical and Research Reports|June 3, 2024
Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having <i>EGFR</i> Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ StudyMadhusmita Behera, Renjian Jiang, Zhonglu Huang, et al.
JCO Oncology Practice|July 8, 2026
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine NeoplasmsJennifer W Carlisle, Katherine O'Reilly, Xiyuan Angel Ji, et al.
Cancer Chemotherapy and Pharmacology|May 27, 2014
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)Rathi N Pillai, Joseph Aisner, Suzanne E Dahlberg, et al.
World Journal of Oncology|October 7, 2017
Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United StatesOlatunji B Alese, Sungjin Kim, Zhengjia Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)Suresh S Ramalingam, Ju-Whei Lee, Chandra P Belani, et al.
Cancer|February 1, 2017
Discussing molecular testing in oncology care: Comparing patient and physician information preferencesAna P M Pinheiro, Rachel H Pocock, Jeffrey M Switchenko, et al.
Molecular Cancer|April 12, 2019
Small Molecule KRAS Agonist for Mutant KRAS Cancer TherapyKe Xu, Dongkyoo Park, Andrew T Magis, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
Innovative Clinical Trials: The LUNG-MAP StudyC E Steuer, V Papadimitrakopoulou, R S Herbst, et al.
American Journal of Clinical Oncology|January 29, 2015
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak TrialsCorey J Langer, Mark A Socinski, Jyoti D Patel, et al.
Pageof 51